Chen Zhu

US Patent:

8329660, Dec 11, 2012

Filed:

Oct 4, 2004

Appl. No.:

10/958169

Inventors:

Vijay K. Kuchroo - Newton MA, US
Terry Strom - Brookline MA, US
Eugene K. Cha - Muttontown NY, US
Sumone Chakravarti - Oakland CA, US
Catherine Sabatos - San Francisco CA, US
Chen Zhu - Brookline MA, US
Xin Xiao Zheng - Wellesley MA, US
Alberto Sanchez-Fueyo - Barcelona, ES

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA
Beth Israel Deaconess Medical Center, Inc. - Boston MA

International Classification:

A61K 39/395

US Classification:

514 212

Abstract:

The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.

US Patent:

20200095284, Mar 26, 2020

Filed:

Nov 6, 2019

Appl. No.:

16/676036

Inventors:

- BOSTON MA, US
VIJAY K. KUCHROO - NEWTON MA, US
YU-HWA HUANG - BOSTON MA, US
CHEN ZHU - BROOKLINE MA, US
ANA C. ANDERSON - BROOKLINE MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - BOSTON MA

International Classification:

C07K 7/08
C07K 14/705
A61K 39/395
A61K 38/10
C07K 16/30
C07K 16/28

Abstract:

Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.

US Patent:

20170058026, Mar 2, 2017

Filed:

Oct 31, 2016

Appl. No.:

15/339218

Inventors:

- Boston MA, US
Chen Zhu - Brookline MA, US
Ana Carrizosa Anderson - Brookline MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA

International Classification:

C07K 16/24
C12N 15/113

Abstract:

Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.

US Patent:

20150284459, Oct 8, 2015

Filed:

Oct 30, 2013

Appl. No.:

14/437354

Inventors:

- Boston MA, US
Chen Zhu - Brookline MA, US
Ana Carrizosa Anderson - Brookline MA, US

International Classification:

C07K 16/24
C07K 16/18
A61K 38/20
A61K 31/713
A61K 38/17

Abstract:

Described herein are novel compositions comprising IL-27 or NFIL-3 modulators (i.e., inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating TIM-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases.

US Patent:

20150225457, Aug 13, 2015

Filed:

Jul 30, 2013

Appl. No.:

14/418726

Inventors:

- Boston MA, US
Vijay K. Kuchroo - Newton MA, US
Yu-Hwa Huang - Boston MA, US
Chen Zhu - Brookline MA, US
Ana C. Anderson - Brookline MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

C07K 7/08
A61K 38/10
A61K 39/395
C07K 14/705

Abstract:

Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.